Selinexor + Azacitidine combination
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-01 — Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study.: Multicenter prospective study (trial-early) of selinexor + azacitidine (or + ruxolitinib) in MDS/MPN overlap syndromes reports 60% ORR with manageable safety profile — first prospective multicenter dataset for this combination in the overlap population. (novelty: 3)
Open questions
Related
Contributing findings
Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study.
01-jul-2026
novelty 3
per-area 3
introduces